Fig 1: WDR12 requires the molecular chaperone CCT7 to stabilize the expression of CD276. (a–c) Analysis of CD276 expression in melanoma cell lines (SK‐MEL‐5 and SK‐MEL‐28) transfected with siNC or siWDR12 (#H1 and #H2). (a) RT‐qPCR, (b) Western blotting analysis of the expression of WDR12 or CD276, and (c) FACS analysis of CD276 expression levels. (d) Functional enrichment analysis of down‐regulated proteins based on mouse proteomics data. (e) Representative TEM images of SK‐MEL‐28 cells transfected with siNC or siWDR12 (red arrows: autolysosome). (f) Western blotting analysis of SQSTM1/p62 and LC3 expression in melanoma cell lines transfected with siNC or siWDR12. (g) Western blotting analysis of CD276 expression in melanoma cells treated with Baf A1 (400 nM) for 4 h. (h) Co‐IP confirmed the interaction among WDR12, CD276, and CCT7. (i) Western blotting analysis of CD276 expression in melanoma cell lines transfected with siNC or siCCT7 (#H1 and #H2). (j) FACS analysis of CD276 expression in melanoma cell lines transfected with siNC or siCCT7. (k) Western blotting analysis of CD276 expression upon WDR12 overexpression and CCT7 knockdown. All data are presented as mean ± SEM and were obtained from three independent experiments. The p‐values were calculated using the unpaired, two‐tailed t‐test. Not significant (ns), p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001. Baf A1, Bafilomycin A1.
Fig 2: Knockdown of WDR12 promotes CD8+ T‐cell infiltration and potentiates antitumor activity. (a–g) C57BL/6 mice were subcutaneously inoculated with negative control (Ctrl) or shWdr12 (#M1 and #M2) treated B16F10 cells. (a) Schematic diagram of the mouse experimental design (n = 5). (b) Tumor growth curves. (c) Terminal tumor weight. (d) The proportion of GZMB+ CD8+ T cells in CD3+ TILs. (e) Representative flow cytometry gating strategy showing GZMB expression in CD8+ T cells. (f) Representative images of CD8 (Green) and GZMB (Red) IF staining in tumor tissues (the cell nuclei stained with DAPI, scale bar = 40 µm). (g) The correlation between the WDR12 expression levels and cancer hallmarks scores was assessed using proteomic data from mice. (h–j) The shWdr12‐B16F10 tumor‐bearing mice were treated with anti‐CD8 antibody or isotype IgG. (h) Schematic diagram of the mouse experimental design (n = 4). (i) Tumor growth curves. (j) Terminal tumor volume (left) and terminal tumor weight (right). All data are presented as mean ± SEM. The p‐values were calculated using the unpaired, two‐tailed t‐test and two‐way ANOVA analysis. Not significant (ns), p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001. TILs, tumor‐infiltrating lymphocytes; GZMB, granzyme B.
Fig 3: The small molecule compound SU14813 targeting WDR12 down‐regulates CD276 and potentiates CD8+ T‐cell antitumor function. (a) Schematic diagram of the computer‐assisted drug screening. (b) Western blotting analysis of CD276 expression in melanoma cell lines treated with SU14813 for 48 h. (c) FACS analysis of CD276 expression in melanoma cell lines treated with SU14813 for 48 h. (d) Pull‐down analysis of SU14813 and WDR12 interaction. (e) BLI monitors the interaction between SU14813 and WDR12. (f) CETSA analysis of SU14813 on the thermal stability of target protein WDR12. SK‐MEL‐28 cells were treated with DMSO or SU14813 (10 µM) for 48 h and then heated at the indicated temperatures. (g) Co‐IP assay analyzed the interaction between WDR12 and CCT7 after treatment with SU14813. (h) Determine the DC50 and EC50 of SU14813 on WDR12. (i) T cell‐mediated tumor cell‐killing assay. SK‐MEL‐28 cells were cocultured with activated T cells (1:2) for 24 h, followed by luciferase assay. (j–m) The B16F10 tumor‐bearing mice were treated with SU14813 or vehicle. (j) The experimental design for SU14813 treatment (n = 5), (k) tumor growth curve (left) and terminal tumor weight (right). (l) The expression of CD276 on the cell membrane of CD45− cells in tumor tissues was detected by flow cytometry. (m)The proportion of CD8+ and GZMB+ CD8+ T cells in CD3 TILs. All data are presented as mean ± SEM. The p‐values were calculated using the unpaired, two‐tailed t‐test and two‐way ANOVA analysis. Not significant (ns), p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001. BLI, bio‐layer interferometry; CETSA, cellular thermal shift assay; EC50, half effective concentration; DC50, half degradation concentration.
Fig 4: Knockdown of WDR12 reduces CD276, the level of which correlates with the efficacy of immunotherapy. (a) The correlation between WDR12 expression and immune regulatory molecules was analyzed using mouse proteomic data. (b) The expression of CD276 on the cell membrane of CD45−‐ cells in tumor tissues was detected by flow cytometry. (c) Representative images of WDR12 (Green) and CD276 (Red) IF staining in tumor tissues (The cell nuclei stained with DAPI, scale bar = 20 µm). (d) The correlation between the expression of WDR12 and CD276 in the proteomics of patients with melanoma immunotherapy. (e) The Xiangya cohort verified the expression differences of CD276 between the R group (n = 21) and the NR group (n = 27). (f) The Kaplan–Meier curve of OS for patients in the high/low expression group of CD276. (g) Sankey diagram demonstrated the association between the WDR12‐CD276 co‐expression network and the response to immunotherapy. (h–j) The shWdr12‐B16F10 tumor‐bearing mice were treated with anti‐PD‐1 antibody or isotype IgG. (h) Schematic diagram of the mouse experimental design (n = 5), (i) tumor growth curves (left) and terminal tumor weight (right). (j) The proportion of CD8+ and GZMB+ CD8+ T cells in CD3 TILs. All data are presented as mean ± SEM. The p‐values were calculated using the unpaired, two‐tailed t‐test and two‐way ANOVA analysis. Not significant (ns), p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001.
Fig 5: Unraveling the dynamic evolution of melanoma and the predictive value of WDR12 for immunotherapy response. (a) The UMAP visualization analysis shows the spatial distribution of six melanoma cell subpopulations (on the left), along with their corresponding treatment response profiles (on the right). (b) Analysis of the OR for tissue distribution propensity of cell subpopulation (OR > 2 indicates preferential distribution; OR < 0.5 indicates avoidance). (c) The differences in the activity of immune‐related pathways among cell subpopulations (the heatmap shows the Z‐score standardized expression). (d) The expression differences of the Mela3 characteristic genes in the anti‐PD‐1 treatment cohort (phs000452.v3.p1) between R and NR. (e) The forest plot presents the univariate Cox regression analysis of Mela3 characteristic genes based on PFS. f, The proportion of treatment response rate based on the expression level of WDR12 (WDR12‐H: high expression group, WDR12‐L: low expression group). (g) The Kaplan–Meier survival curve shows the impact of the WDR12 expression level on the PFS and OS of patients. (h) Correlation analysis of the WDR12 expression level and infiltration of antitumor immune cells. (i) Representative immunohistochemical images showing WDR12 expression in patients with different treatment responses (scale bar = 100 µm). (j) The Xiangya cohort verified the expression differences of WDR12 between R group (n = 21) and NR group (n = 27). (k) The Kaplan–Meier curve of OS for patients in the high/low expression group of WDR12. *p < 0.05, **p < 0.01, ***p < 0.001. NR, nonresponse to immunotherapy; R, response to immunotherapy; PFS, progression‐free survival; OS, overall survival.
Supplier Page from CUSABIO Technology LLC for Customized Human WDR12 Protein